Mizacorat is a potent, orally active, non-steroidal and selective glucocorticoid receptor modulator (SGRM) with an IC50 of 3.8 nM. It has demonstrated superior efficacy in a streptococcal cell wall (SCW) reactivation model of joint inflammation[1].
Mizacorat 细胞实验
Cell Line
Concentration
Treated Time
Description
References
primary CD4+ T cells
0.01 µM–10 µM
24 hours and 48 hours
AZD9567 triggered luciferase expression even at the lowest concentration tested (0.01 µM)
J Virol. 2025 Feb 25;99(2):e0188624
U1 cells
0.01 µM–10 µM
48 hours and 96 hours
AZD9567 consistently reactivated HIV-1 in all cell lines tested
J Virol. 2025 Feb 25;99(2):e0188624
ACH-2 cells
0.01 µM–10 µM
48 hours and 96 hours
AZD9567 consistently reactivated HIV-1 in all cell lines tested
J Virol. 2025 Feb 25;99(2):e0188624
J-Lat 10.6 cells
0.01 µM–10 µM
48 hours and 96 hours
AZD9567 consistently reactivated HIV-1 in all cell lines tested
J Virol. 2025 Feb 25;99(2):e0188624
Hela cells
10 μM
18 hours
GR ligand binding test, 16 compounds at 10 μM exhibit good inhibition activities (>70%)
Adv Sci (Weinh). 2022 Jan;9(3):e2102435
Raw264.7 cells
25 μM
48 hours
Cytotoxicity test, 72 compounds do not affect cell viability at 25 μM
Adv Sci (Weinh). 2022 Jan;9(3):e2102435
Mizacorat 动物研究
Animal study
Mizacorat inhibited SCW-induced ankle swelling in a rat model of joint inflammation when administered orally daily for 8 days at a dose of 15 mg/kg[1].
搜索
